Posted by Michael Wonder on 09 Apr 2018
NICE u-turn sees Roche’s Tecentriq backed for lung cancer
9 April 2018 - Roche starts the week on a positive note with a NICE recommendation after two rejections from NICE last
week.
Following an earlier negative decision NICE is now recommending NHS use of Roche’s immunotherapy Tecentriq for lung cancer.
The guidelines endorse use of the drug to treat patients with non-small cell lung cancer whose disease has progressed following standard chemotherapy.
Tecentriq blocks PD-L1 - an important ligand found on the surface of cancer cells that camouflage them from detection and destruction by the immune system.
